Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CnU
- Development stage
- Phase 4
- Lead developer
- Myungmoon Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CnU is a pharmaceutical drug developed by Myungmoon Pharma. Co. Ltd. It is a combination drug containing Magnesium Salt Trihydrate of Chenodeoxycholic Acid and Ursodeoxycholic Acid. It is administered orally and is currently in Phase 3 clinical trials for the treatment of biliary dyspepsia and cholesterol gallstones. Its therapeutic effects stem from the combined actions of its bile acid components, which modulate cholesterol metabolism and bile flow.
- Brand names
- CnU Cap.CnU capsule
- Other names
- Chenodeoxycholic Acid-Ursodeoxycholic Acid Magnesium Salt TrihydrateCDCA-UDCA magnesium salt trihydrate
02
Targets
PXR (Pregnane X receptor)GPBAR1
Beyond the preview
Go deeper on CnU.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CnU.